Loading
Nanobiotix Stock: price and insider trades · France
1 insider bought €227k of shares over the last 90 days, the latest filed 20 Jul 2026.
Nanobiotix: what insiders have been doing
Nanobiotix, classified in the Healthcare & Pharma sector, is a listed company based in Paris, France, founded in 2003. Its insiders report their share dealings to AMF. From 18 October 2025 to 18 October 2026, the disclosure feed for Nanobiotix logged 4 filings by 2 insiders.
The record shows 3 purchases on the open market worth €281k, made by 1 insider, against 1 sale worth €5.1M by 1 insider. On balance, insiders were net sellers of €4.8M. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Among those who bought: 1 board member and 1 chief executive. At €5.1M, the sale published on 3 December 2025 by Laurent Levy is the largest of the period.
The last purchase on record was published on 20 July 2026, which is 89 days ago. Filings reach the AMF feed a median of 3 days after the trade. For comparison, MAR article 19 gives managers three business days to notify a trade.
Across the 316 companies tracked on its exchange, the median is 6 filings; at 4 filings, this issuer sits below that mark. Since 2023, the database holds 13 purchases and 1 sale by insiders of the company.
For comparison within the same sector, see the insider buying recorded at Cooper Companies, Inc. and Cytosorbents Corp. Source: insider filings from AMF. Past trades are no guide to future returns.
Insider Decl.
19
Thresholds
n/a
Buy Volume
€753,599
13 ops. · all time
Sell Volume
€5M
1 ops. · all time
Who traded when
BuySaleBartholomeus van Rhijn8 buys
Gary Phillips4 buys
Anne-Marie Graffin1 buy
Laurent LEVY1 sale
Since the insiders bought
- +9.4%Entry €34.78 · Close at T+30 €38.04
- +798.1%Entry €3.67 · Close at T+365 €32.96
- +837.2%Entry €2.96 · Close at T+365 €27.74
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Financial data
as of FY 2025FY ended December 2025 · cache
€19.69
Analyst consensus
5 analysts1.00/5
€40.00Target €52.20(+165%)€60.00
Income statement
Revenue€29.6M
EBITDA-€12.1M-41% margin
Net income-€24.0M-80.8% margin
Valuation
PER (forward)-78.8x
Beta0.59
Balance sheet & cash
Market cap€1.0B
Total debt€95.3M
Free Cash Flow-€34.0M
Profitability & ownership
ROA-21.3%
% insiders15.5%
% institutions29.4%
Last declaration on 20 July 2026
Declarations19 total
6,114 shares@ €37.07620.015% mcap67.6% of flowActionNASDAQISIN FR00113412052026DD1127610
Canonical exit: 14 Oct 2026 (T+90)
1,100 shares@ US$26.61757.4% of flowActionNASDAQISIN FR00113412052026DD1095929
Canonical exit: 18 May 2026 (T+90)
1,500 shares@ US$23.628.9% of flowActionNASDAQISIN FR00113412052026DD1094586
Canonical exit: 12 May 2026 (T+90)
295,000 shares@ €17.2794100.0% of flowActionEuronext ParisISIN FR00113412052025DD1072320
130,780 shares@ €4.04100.0% of flowActionHors plateforme de négociationISIN FR00113412052025DD1045725
40,000 shares@ €4.04100.0% of flowActionHors plateforme de négociationISIN FR00113412052025DD1045718
400,232 shares@ €4.04100.0% of flowActionHors plateforme de négociationISIN FR00113412052025DD1045722
66,708 shares@ €4.04100.0% of flowActionHors plateforme de négociationISIN FR00113412052025DD1045711
11,000 shares@ US$5.622316.1% of flowActionNASDAQISIN FR00113412052025DD1043164
Canonical exit: 11 Sept 2025 (T+90)
10,780 shares@ €3.41459.3% of flowActionEuronext ParisISIN FR00113412052025DD1039917
Canonical exit: 24 Aug 2025 (T+90)
3,610 shares@ €3.313.0% of flowActionEuronext ParisISIN FR00113412052025DD1039719
Canonical exit: 19 Aug 2025 (T+90)
10,000 shares@ €2.907.3% of flowActionEuronext ParisISIN FR00113412052025DD1038006
Canonical exit: 10 Aug 2025 (T+90)
7,400 shares@ €3.0582100.0% of flowActionEuronext ParisISIN FR00113412052025DD1032182
Canonical exit: 14 Jul 2025 (T+90)
2,038 shares@ €2.8121.4% of flowActionEuronext ParisISIN FR00113412052025DD1031953
Canonical exit: 8 Jul 2025 (T+90)
30,000 shares@ €3.061823.2% of flowActionEuronext ParisISIN FR00113412052025DD1031083
Canonical exit: 2 Jul 2025 (T+90)
13,390 shares@ €3.302711.2% of flowActionEuronext ParisISIN FR00113412052024DD1011383
Canonical exit: 11 Mar 2025 (T+90)
25,000 shares@ €3.26920.7% of flowActionEuronext ParisISIN FR00113412052024DD1011386
Canonical exit: 12 Mar 2025 (T+90)
30,600 shares@ €3.086323.9% of flowActionEuronext ParisISIN FR00113412052024DD1011001
Canonical exit: 9 Mar 2025 (T+90)
959,060 shares0ActionHors plateforme de négociationISIN FR00113412052023DD896264
19 of 19 declarations
About Nanobiotix
Nanobiotix is a French late-stage clinical biotechnology company focused on developing innovative nanotherapeutic approaches, primarily for oncology. Founded in 2003 following a spin-off from research work linked to the University at Buffalo, the company is headquartered in Paris and also maintains an operational footprint in the United States, including Cambridge, Massachusetts, and New York. It has been listed on Euronext Paris since 2012 and on the Nasdaq Global Select Market since December 2020.
The company’s business model is built around a physics-based therapeutic approach that leverages nanoparticles and nanomedicine to enhance the effectiveness of existing treatments. Its flagship program is NBTXR3, described as a first-in-class radioenhancer designed to be injected into a tumor and activated by radiotherapy in order to intensify the radiation dose delivered to cancer cells. Beyond oncology, Nanobiotix states that it owns and develops multiple nanotechnology platforms with potential applications in bioavailability and biodistribution, as well as certain central nervous system disorders.
Read moreShow less
Strategically, Nanobiotix is positioned as a late-stage biotech company aiming to materially change how radiotherapy is used in cancer care, rather than offering a conventional supportive therapy. This ambition is supported by a patent estate covering several nanotechnology platforms and by key strategic partnerships. A particularly important milestone is its global licensing and co-development agreement with Janssen Pharmaceutica NV, part of Johnson & Johnson, for the commercialization pathway of its lead radioenhancer program.
Historically, the company has been marked by deep scientific roots, intensive R&D investment and gradual international expansion. Its structure combines research, clinical development, manufacturing and potential commercialization capabilities, with a French base and U.S. operations supporting its global ambitions. Nanobiotix targets the worldwide oncology market, offering substantial upside potential but also the elevated execution and regulatory risk typical of clinical-stage biopharmaceutical companies. As of March 31, 2026, the company reported cash and cash equivalents of €52.8 million at December 31, 2025 and stated that its current operating plan could fund operations into early 2028, subject to certain additional funding conditions.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
